PubMed · 2022

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Ji L, Gao L, Jiang H, Yang J (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine.

EClinicalMedicine

This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.